Fresenius Kabi, Akorn in Talks for Possible Merger
Akorn, a Lake Forest, Illinois-headquartered specialty generic pharmaceutical company, has confirmed that it is currently in discussions with Fresenius Kabi, a specialty and generic pharmaceuticals company and a subsidiary of Fresenius SE & Co. KGaA, a Bad Homburg, Germany-headquartered healthcare group, concerning a potential acquisition of Akorn by Fresenius Kabi.
Entry into a formal agreement with respect to a transaction remains subject to approval by the executive board and supervisory board of Fresenius Management SE and the board of directors of Akorn. “There can be no assurance any transaction will result from these discussions, or as to the terms of any such transaction,” said Akorn in a company statement. “Neither Fresenius SE nor Akorn intend to make any additional comments regarding these negotiations unless and until it is appropriate to do so, or a formal agreement has been reache,” said Akorn in the statement.
Akorn and Fresenius Kabi are specialty pharmaceutical companies that have contract manufacturing activities and that specialize in sterile manufacturing. Akorn has manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland; and Paonta Sahib, India that manufacture ophthalmic, injectable, and specialty sterile and non-sterile pharmaceuticals. Fresenius Kabi specializes in intravenous medicines and offers injectable and specialty pharmaceutical products focused on the oncology, anti-infective, anesthetic/analgesic, and critical care markets. Fresenius Kabi Product Partnering provides contract sterile manufacturing.